BRIEF — Shionogi seeks Japanese approval for ADHD drug for adults

Japanese drugmaker Shionogi has applied for approval to manufacture and sell Intuniv (guanfacine hydrochloride) tablets attention for adults with attention deficit hyperactivity disorder (ADHD) in Japan.

Together with its partner, the Ireland-based firm Shire, Shionogi has developed Intuniv and the Osaka-based company launched it for pediatric ADHD patients in Japan in May 2017.